On August 5, TG Therapeutics rose 5.01% in regular trading, trading at approximately $48.49 per share, with turnover of approximately $90.52 million.

The rebound follows the market's reassessment of the company's Q2 results, which showed total global revenue of approximately $240 million, exceeding the consensus estimate of $230 million. The company simultaneously raised its full-year BRIUMVI revenue guidance. The stock had previously declined approximately 7% after reporting Q2 earnings per share of just $0.05, significantly missing the analyst consensus estimate of $0.33 — representing an 84.85% shortfall and marking the third consecutive quarter of EPS missing expectations.

The current recovery suggests investors are shifting focus toward the top-line strength and improved revenue outlook. TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell mediated diseases, with its core product BRIUMVI approved in the U.S., EU, and UK for relapsing forms of multiple sclerosis. The company has also been expanding BRIUMVI's pipeline into myasthenia gravis and treatment-resistant schizophrenia.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)